Amendment to aluminium P1020A MJP quarterly premium methodology

Fastmarkets has amended its aluminium P1020A (MJP) quarterly premium assessment methodology.

After a one-month consultation period, Fastmarkets has amended the publishing deadline for its assessment of the aluminium P1020A main Japanese ports (MJP) quarterly premium, cif Japan. It will be published at the end of the first month of the said quarter instead of on the 15th day of the first month of the said quarter.

This is due to the settlement taking place later than usual – in the first month of the contract quarter – in recent quarters throughout 2022.

The deadline is part of the fall-back procedures. The settlement can still be published before the revised deadline when more than 30,000 tonnes of contracted business have been reported by a consumer, producer and trader.

To provide feedback on this price, or if you would like to provide price information by becoming a data submitter, please contact Alice Mason by email at: pricing@fastmarkets.com. Please add the subject heading FAO: Alice Mason, re: aluminium MJP quarterly.

To see all Fastmarkets’ pricing methodology and specification documents go to https://www.fastmarkets.com/about-us/methodology

What to read next
The low-carbon aluminium differential in the US made its first move on Friday April 5 since Fastmarkets launched it five months ago.
Fastmarkets proposes to amend the specifications of five of its steel products assessments and billet index originating from the Black Sea basin.
Fastmarkets launched a suite of CIF India aluminium scrap prices on Wednesday April 17.
Fastmarkets is inviting feedback from the industry on the methodology for its audited non-ferrous price assessments, as part of its announced annual methodology review process.
Brazil's aluminium industry is further enhancing its sustainability by boosting renewable energy use and recycling, while mitigating risk from high-carbon imports
German copper producer Aurubis is among the least likely to consider reducing capacity despite record low treatment charges (TCs), according to its chief executive officer